6-Feb-2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 5-Feb 4:00 PM ET)
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Globe Newswire (Thu, 5-Feb 9:26 AM ET)
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Business Wire (Wed, 4-Feb 8:00 AM ET)
Immunome (IMNM) Receives a Buy from Wedbush
TipRanks (Tue, 3-Feb 4:56 PM ET)
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
Business Wire (Tue, 6-Jan 8:00 AM ET)
Immunome's $400 Million Public Offering Draws Focus to Cancer Therapy Pipeline and Investor Demand
Market Chameleon (Wed, 17-Dec 2:55 AM ET)
Immunome Announces Pricing of Public Offering of Common Stock
Business Wire (Tue, 16-Dec 8:16 PM ET)
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Globe Newswire (Tue, 16-Dec 12:18 PM ET)
Immunome Announces Proposed Public Offering of Common Stock
Business Wire (Mon, 15-Dec 4:01 PM ET)
Immunome to Reveal Pivotal Phase 3 Results for Varegacestat in Desmoid Tumors—What’s at Stake?
Market Chameleon (Mon, 15-Dec 5:28 AM ET)
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Immunome trades on the NASDAQ stock market under the symbol IMNM.
As of February 6, 2026, IMNM stock price climbed to $24.88 with 1,092,313 million shares trading.
IMNM has a beta of 1.14, meaning it tends to be more sensitive to market movements. IMNM has a correlation of 0.10 to the broad based SPY ETF.
IMNM has a market cap of $2.75 billion. This is considered a Mid Cap stock.
Last quarter Immunome reported $0 in Revenue and -$.65 earnings per share. This fell short of revenue expectation by $-727,270 and missed earnings estimates by -$.10.
In the last 3 years, IMNM traded as high as $30.96 and as low as $4.04.
The top ETF exchange traded funds that IMNM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
IMNM has outperformed the market in the last year with a return of +117.7%, while the SPY ETF gained +15.1%. In the last 3 month period, IMNM beat the market returning +60.5%, while SPY returned +3.3%. However, in the most recent 2 weeks IMNM has underperformed the stock market by returning -3.8%, while SPY returned +0.2%.
IMNM support price is $22.77 and resistance is $25.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMNM shares will trade within this expected range on the day.